Patents by Inventor Muralidhara Ramachandra
Muralidhara Ramachandra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180072689Abstract: The present invention relates to synthetic methods for 1,2,4-oxadiazole compounds. The general synthetic scheme is: R1 substituents generally are optionally substituted methanol or ethanol moieties, R3 substituents generally are optionally substituted acetic or propanoic acids or their amides and Aaa is Thr or Ser which has a free, amidated or esterified C-terminus.Type: ApplicationFiled: September 24, 2017Publication date: March 15, 2018Applicant: Aurigene Discovery Technologies LimitedInventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli
-
Publication number: 20180044304Abstract: The present invention relates to 1,3,4-oxadiazole and thiadiazole compounds of formula (I) and their use to inhibit the programmed cell death 1 (PD-1) signaling pathway and/or for treatment of disorders by inhibiting an immunosuppressive signal induced by PD-1, PD-L1 or PD-L2.Type: ApplicationFiled: March 8, 2016Publication date: February 15, 2018Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli
-
Publication number: 20180044305Abstract: The present invention relates to 3-substituted 1,3,4-oxadiazole and thiadiazole compounds of formula (I) and their use to inhibit the programmed cell death 1 (PD-1) signaling pathway and/or for treatment of disorders by inhibiting an immunosuppressive signal induced by PD-1, PD-L1 or PD-L2.Type: ApplicationFiled: March 10, 2016Publication date: February 15, 2018Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Appukkutan Prasad, Seetharamaiah Setty Sudarshan Naremaddepalli
-
Publication number: 20180044329Abstract: The present invention relates to 3-substituted-1,2,4-oxadiazole and thiadiazole compounds of formula (I) or formula (II) and their use to inhibit the programmed cell death 1 (PD-1) signaling pathway and/or for treatment of disorders by inhibiting an immunosuppressive signal induced by PD-1, PD-L1 or PD-L2.Type: ApplicationFiled: March 9, 2016Publication date: February 15, 2018Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Appukkuttan Prasad, Seetharamaiah Setty Sudarshan Naremaddepalli
-
Publication number: 20180044350Abstract: The present invention relates to cyclic compounds of formula (I) and their use to inhibit the programmed cell death 1 (PD-1) signaling pathway and/or for treatment of disorders by inhibiting an immunosuppressive signal induced by PD-1, PD-L1 or PD-L2.Type: ApplicationFiled: March 7, 2016Publication date: February 15, 2018Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli
-
Publication number: 20180044303Abstract: The present invention relates to 1,2,4-oxadiazole compounds of formula (I) and their use to inhibit the programmed cell death 1 (PD-1) signaling pathway and/or for treatment of disorders by inhibiting an immunosuppressive signal induced by PD-1, PD-L1 or PD-L2.Type: ApplicationFiled: March 7, 2016Publication date: February 15, 2018Inventors: Pottayil Govindan N. Sasikumar, Muralidhara Ramachandra, Seetharamaiah Sudarshan Naremaddepalli
-
Patent number: 9783578Abstract: The present invention provides immunosuppression compounds to inhibit the programmed cell death 1 (PD1) signalling pathway. The present invention further provides peptide based compositions for treatment of cancer or treatment of infections via immunopotentiation caused by inhibition of immunosuppressive signaling induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient. Further, the invention provides an application of the compositions containing the peptide moieties for preventive and/or therapeutic agents for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of peptide moieties as a testing or diagnostic agent or a research agent for such a disease.Type: GrantFiled: December 8, 2014Date of Patent: October 10, 2017Assignee: AURIGENE DISCOVERY TECHNOLOGIES LIMITEDInventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Suresh Kumar Vadlamani, Koteswara Rao Vemula, Leena Khare Satyam, Krishnaprasad Subbarao, K. Rajeev Shrimali, Sreenivas Kandepu
-
Patent number: 9776978Abstract: The present invention relates to 1,3,4-oxadiazole and 1,3,4-thiadiazole compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also refers to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.Type: GrantFiled: October 18, 2016Date of Patent: October 3, 2017Assignee: Aurigene Discovery Technologies LimitedInventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli
-
Patent number: 9771338Abstract: The present invention relates to 1,2,4-oxadiazole and 1,2,4-thiadiazole compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signaling pathway. The invention also refers to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.Type: GrantFiled: October 20, 2016Date of Patent: September 26, 2017Assignee: Auirgene Discovery Technologies LimitedInventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli
-
Publication number: 20170101387Abstract: The present invention relates to 1,3,4-oxadiazole and 1,3,4-thiadiazole compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also refers to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.Type: ApplicationFiled: October 18, 2016Publication date: April 13, 2017Applicant: Aurigene Discovery Technologies LimitedInventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli
-
Publication number: 20170101386Abstract: The present invention relates to 1,2,4-oxadiazole and 1,2,4-thiadiazole compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signaling pathway. The invention also refers to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.Type: ApplicationFiled: October 20, 2016Publication date: April 13, 2017Applicant: Aurigene Discovery Technologies LimitedInventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli
-
Publication number: 20170101444Abstract: The present invention relates to cyclic peptidomimetic compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also relates to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.Type: ApplicationFiled: October 24, 2016Publication date: April 13, 2017Applicant: Aurigene Discovery Technologies LimitedInventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli
-
Patent number: 9422339Abstract: The present invention relates to novel cyclic compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also relates to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.Type: GrantFiled: March 28, 2013Date of Patent: August 23, 2016Assignee: Aurigene Discovery Technologies LimitedInventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra
-
Publication number: 20160194295Abstract: The present invention relates to 1,3,4-oxadiazole and 1,3,4-thiadiazole compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also refers to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.Type: ApplicationFiled: September 5, 2014Publication date: July 7, 2016Applicant: Aurigene Discovery Technologies LimitedInventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli
-
Publication number: 20160113901Abstract: The present invention relates to cyclic peptidomimetic compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also relates to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.Type: ApplicationFiled: January 7, 2016Publication date: April 28, 2016Applicant: Aurigene Discovery Technologies LimitedInventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli
-
Patent number: 9233940Abstract: Compounds of Formula (I) are provided: and pharmaceutically acceptable salts and stereoisomers thereof; wherein: R1 is a side chain of amino acid Ala, Ser, Thr or Leu; R2 is a side chain of amino acid Asp, Glu, Gln or Asn; [Aaa] is an amino acid residue selected from Ser, ASP, Ala, Ile, Phe, Trp, Lys, Glu or Thr; R3 is hydrogen or alkyl; each of R4 and R4? independently are hydrogen or alkyl; both Ra and Ra? are hydrogen; or together are an oxo (?O) group; both Rb and Rb? are hydrogen; or together are an oxo (?O) group; L is X is CH2, O or S; R5 is hydrogen or alkyl; m is an integer from 1 to 3; and n is an integer from 2 to 20. The compounds are useful for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.Type: GrantFiled: September 5, 2014Date of Patent: January 12, 2016Assignee: Aurigene Discovery Technologies LimitedInventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli
-
Patent number: 9096642Abstract: The present invention provides Immunosuppressive compounds capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The present invention further provides peptide based compositions for treatment of cancer or treatment of infections via immunopotentiation caused by inhibition of immunosuppressive signalling induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient. Further, the invention provides pharmaceutical compositions comprising the Immunosuppressive peptide compounds or modified peptide moieties for preventive and/or therapeutic agents for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of PD-1 or PD-L1 as a testing or diagnostic agent or a research agent for such a disease.Type: GrantFiled: December 21, 2011Date of Patent: August 4, 2015Assignee: Aurigene Discovery Technologies LimitedInventors: Pottayil G. N. Sasikumar, Muralidhara Ramachandra, Suresh Kumar Vadlamani, K. Rajeev Shrimali, Krishnaprasad Subbarao
-
Patent number: 9044442Abstract: The present invention relates to novel peptidomimetic compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also relates to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.Type: GrantFiled: March 7, 2013Date of Patent: June 2, 2015Assignee: Aurigene Discovery Technologies LimitedInventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli
-
Publication number: 20150125491Abstract: The present invention relates to novel cyclic compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also relates to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.Type: ApplicationFiled: March 28, 2013Publication date: May 7, 2015Applicant: Aurigene Discovery Technologies LimitedInventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra
-
Publication number: 20150087581Abstract: The present invention provides immunosuppression compounds to inhibit the programmed cell death 1 (PD1) signalling pathway. The present invention further provides peptide based compositions for treatment of cancer or treatment of infections via immunopotentiation caused by inhibition of immunosuppressive signaling induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient. Further, the invention provides an application of the compositions containing the peptide moieties for preventive and/or therapeutic agents for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of peptide moieties as a testing or diagnostic agent or a research agent for such a disease.Type: ApplicationFiled: December 8, 2014Publication date: March 26, 2015Applicant: AURIGENE DISCOVERY TECHNOLOGIES LIMITEDInventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Suresh Kumar Vadlamani, Koteswara Rao Vemula, Leena Khare Satyam, Krishnaprasad Subbarao, K. Rajeev Shrimali, Sreenivas Kandepu